Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis by Lastrucci, Claire et al.
ORIGINAL ARTICLE
npgCell Research (2015) :1-19.
© 2015 IBCB, SIBS, CAS    All rights reserved 1001-0602/15  $ 32.00
www.nature.com/cr
Tuberculosis is associated with expansion of a motile, 
permissive and immunomodulatory CD16+ monocyte 
population via the IL-10/STAT3 axis
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The human CD14+ monocyte compartment is composed by two subsets based on CD16 expression. We previ-
ously reported that this compartment is perturbed in tuberculosis (TB) patients, as reflected by the expansion of 
CD16+ monocytes along with disease severity. Whether this unbalance is beneficial or detrimental to host defense 
remains to be elucidated. Here in the context of active TB, we demonstrate that human monocytes are predisposed 
to differentiate towards an anti-inflammatory (M2-like) macrophage activation program characterized by the 
CD16+CD163+MerTK+pSTAT3+ phenotype and functional properties such as enhanced protease-dependent motility, 
pathogen permissivity and immunomodulation. This process is dependent on STAT3 activation, and loss-of-function 
experiments point towards a detrimental role in host defense against TB. Importantly, we provide a critical correla-
tion between the abundance of the CD16+CD163+MerTK+pSTAT3+ cells and the progression of the disease either at 
the local level in a non-human primate tuberculous granuloma context, or at the systemic level through the detection 
of the soluble form of CD163 in human sera. Collectively, this study argues for the pathogenic role of the CD16+C-
D163+MerTK+pSTAT3+ monocyte-to-macrophage differentiation program and its potential as a target for TB thera-
py, and promotes the detection of circulating CD163 as a potential biomarker for disease progression and monitoring 
of treatment efficacy.
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Introduction
Tuberculosis (TB) is a severe chronic bacterial infec-
tion caused by Mycobacterium tuberculosis (Mtb). In 
2013, TB claimed the life of nearly 1.5 million people, 
ranking this disease as the second leading cause of death 
from a single infectious agent (Global TB report, WHO, 
2014). While TB mortality is slowly declining each year, 
it is still unacceptably high given that most cases would 
be curable if better diagnostic tools and correct treatment 
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were available to complement existing technologies. A 
major obstacle is the lack of TB-specific and non-specific 
immune activation biomarker and bio-signature tools to 
estimate disease severity, follow drug treatment efficacy, 
allow prognosis of disease outcome (recovery or relapse) 
and estimate vaccine protection [1, 2]. As the basis for 
maintaining the flow of novel biomarker candidates in 
the product pipeline, fundamental science is necessary to 
better characterize Mtb interaction with the human host. 
Innate immunity plays a key role in host defense 
against Mtb. Among the immune innate cells involved 
in this resistance, macrophages are primordial regulators 
of the balance of pro- and anti-inflammatory immune 
response in order to ensure the control of bacterial rep-
lication and limit the extent of tissue damage following 
pathogenic insult [3-5]. They perform these roles accord-
ing to their high degree of phenotypic and functional 
plasticity in response to environmental clues within tis-
sues, and are classified within a spectrum ranging from 
pro-inflammatory (M1) to anti-inflammatory (M2) acti-
vation programs [6]. Remarkably, Mtb displays a great 
capacity to influence the differentiation, maturation and 
activation of macrophages, resulting in an effective eva-
sion of the immune response and increased persistence 
in the host (for review, see [7-9]). Despite the signifi-
cant progress in understanding macrophage subversion 
by Mtb, one aspect that remains poorly studied is how 
monocytes contribute to the dynamic alteration of the 
macrophage compartment during ongoing Mtb infection. 
As monocytes are the precursors of macrophages during 
inflammation, substantial insights into host defenses are 
likely to be gained by determining the role of these leu-
kocytes within the TB context. In particular, while there 
are important clues coming from the zebrafish and mouse 
models, the human context remains poorly explored [7, 9, 
10].
Human blood monocytes are broadly segregated 
into two major subsets: CD14+CD16− (classical) and 
CD14+CD16+ (non-classical) monocytes, hereafter des-
ignated as CD16− and CD16+, respectively [11, 12]. 
Notably, the CD16+ subset accounts for only 10% of the 
total monocyte population in healthy donors, displaying 
a unique cell-surface marker expression and cytokine se-
cretion pattern in comparison with its CD16− counterpart 
[13, 14]. Indeed, upon stimulation with lipopolysaccha-
ride, CD16+ monocytes isolated from healthy donors se-
crete higher amounts of pro-inflammatory factors such as 
tumor necrosis factor-alpha (TNFα), interleukin-1-beta 
(IL-1) and IL-6, but low amount of the anti-inflammatory 
mediator IL-10 [13, 15-17]. Other features distinguishing 
the CD16+ subset are higher antigen processing and pre-
sentation, pro-angiogenic behavior and motility [10]. The 
expansion of CD16+ monocytes is well documented in 
different types of diseases, mainly deriving from infec-
tion or inflammatory conditions [10]. For these reasons, 
CD16+ monocytes are usually referred to as pro-inflam-
matory monocytes.
Interestingly, the human monocyte compartment is 
perturbed in TB patients, as illustrated by the expansion 
of CD16+ monocytes, which can account for up to 50% 
of the total monocyte population, and its correlation with 
the disease severity [18]. This unbalance in the monocyte 
population is also associated with a higher cell-surface 
expression for CD14, CD11b, toll-like receptor-2 (TLR2), 
TLR5, chemokine C-C motif receptor-1 (CCR1), CCR2 
and CCR5, as compared with that of healthy individu-
als [18]. Functional characterization in vitro shows that 
monocytes isolated from TB patients are refractory to 
efficient dendritic cell (DC) differentiation and deficient 
in the activation of T lymphocytes, as compared with 
monocytes from healthy donors [19, 20]. The cause and 
consequence of this unbalance are still relatively un-
known. In addition, it remains to be elucidated whether 
there is an effect on the ability of monocytes from TB 
patients to differentiate into macrophages that are capa-
ble of controlling the bacilllus’ intracellular growth and 
mount an effective immune response. Indeed, this is a 
critical functional aspect to assess, along with its prog-
nostic value, in order to determine whether the unbal-
anced monocyte population is beneficial or detrimental 
to host defense against TB, and whether this represents a 
potential bio-signature and target for treatment.
Here we describe that, in the context of TB, human 
monocytes differentiating towards a macrophage pro-
gram (referred here to as monocyte-macrophages) are 
tilted towards an M2-like activation program charac-
terized by the CD16+CD163+MerTK+pSTAT3+ marker 
phenotype and functional properties such as high pro-
tease-dependent motility, pathogen permissivity and 
immunomodulatory activity. The establishment of this 
program is mainly dependent on the signal transduc-
er and activator of transcription 3 (STAT3)-dependent 
signaling pathway, and points towards a detrimental 
role in host defense against TB. Importantly, our study 
provides direct correlation of the abundance of CD16+C-
D163+MerTK+pSTAT3+ cells with TB disease severity in 
humans and non-human primates (NHPs), and proposes 
the presence of the soluble form of CD163 (sCD163) in 
sera as a potential biomarker to monitor disease progres-
sion and treatment efficacy.
Results
The secretome of Mtb-infected macrophages favors the 
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differentiation of human monocytes towards an M2-like 
activation program
Mtb infection is known to significantly alter monocyte 
differentiation upon recruitment to pulmonary tissue in 
mice, alluding to a bystander effect derived from infect-
ed resident cells [21]. As the secretome of Mtb-infected 
macrophages inhibits human monocyte differentiation 
towards DC program [22], we investigated whether it 
also alters monocyte-to-macrophage differentiation. To 
this aim, we devised an in vitro model whereby freshly 
isolated CD14+ monocytes from healthy donors were dif-
ferentiated towards a macrophage program (M-CSF driv-
en) in the presence of conditioned media from Mtb-in-
fected human macrophages (cmMTB). As a control, we 
differentiated monocytes using a conditioned media from 
non-infected macrophages (cmCTR). Unlike treatment 
with cmCTR, we observed an expansion of the CD16+ 
population in the cmMTB-treated monocytes (Figure 
1A). In addition, we assessed their activation program 
by flow cytometry in terms of M1 and M2 cell-surface 
marker expression. Monocytes conditioned with cmMTB 
differentiated into cells displaying an equivalent or low-
Figure 1 The secretome of Mtb-infected macrophages induces the differentiation of CD16+ monocytes towards an M2-like 
phenotype. Monocytes were cultured with conditioned media from Mtb-infected (cmMTB, black) or non-infected (cmCTR, 
white) macrophages. (A) Flow cytometry gating strategy of a representative donor and the percentage of CD14+CD16+ cells. 
(B) Vertical scatter plots showing the median fluorescent intensity (MFI) of cell-surface markers during cmCTR or cmMTB 
treatment. (C) Vertical scatter plots showing the MFI of CD163, MerTK or CD206 in the CD14+CD16− (white circles) and 
CD14+CD16+ (black circles) cell populations during cmCTR or cmMTB treatment. *P < 0.05, **P < 0.01, ***P < 0.001. Each 
circle within vertical scatter plots represents a single donor.
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er expression of M1 polarization markers (i.e., CD86, 
HLA-DR, FCAR and Serpine1) compared with cells 
differentiated in the presence of cmCTR (Supplementary 
information, Figure S1A-S1B). By contrast, the expres-
sion of markers related to M2 macrophage activation, 
such as CD16, CD163, MerTK, CD206, AMAC1 and 
CD200R1 [23-27], was upregulated in cmMTB-con-
ditioned cells (Figure 1B, Supplementary information, 
Figure S1B). Similarly, the expression of CCR2 and 
CCR5 chemokine receptors was higher in the presence of 
cmMTB, supporting the acquisition of the M2 program 
(Supplementary information, Figure S1C) [28, 29]. More 
precisely, the expression of M2 markers was specifically 
augmented within CD16+ population compared with the 
CD16− counterpart, with a higher increase of CD163 and 
CD206 upon cmMTB treatment monocytes (Figure 1C). 
    These results indicate that soluble factors secreted by 
Mtb-infected macrophages exert bystander effect affect-
ing monocyte differentiation towards an M2-like activa-
tion program.
The monocyte activation towards CD16+CD163+MerTK+ 
phenotype is dependent on the IL-10/STAT3 signaling 
pathway in the TB context
In the presence of M-CSF, IL-10 triggers macrophage 
M2 activation that promotes tolerance mechanisms, in-
cluding the resolution of inflammation and tissue repair 
[28, 30]. Moreover, this cytokine is not only increased in 
serum and pleural effusion from TB patients compared 
with healthy donors [31, 32], but also in the lungs of 
Mtb-infected NHPs [33]. As IL-10 is secreted by Mtb-in-
fected human macrophages [34], we investigated wheth-
er it is responsible for the Mtb-derived bystander effect 
observed in our in vitro model. We first examined wheth-
er human recombinant IL-10 (recIL-10), in combination 
with M-CSF, recapitulated the effect of the cmMTB. As 
expected, the expression of CD206 was not influenced 
by recIL-10, rather confirming the regulation of this re-
ceptor by IL-4/STAT6 axis [35]. By contrast, recIL-10 
treatment on monocytes stimulated the expression of M2 
markers (i.e., CD16, CD163 and MerTK) compared with 
control cells, whereas M1 markers were significantly 
decreased (Supplementary information, Figure S2A). 
Moreover, when IL-10 was depleted from cmMTB using 
blocking antibodies (Supplementary information, Figure 
S2B), we observed impairment in the establishment of 
the M2 marker signature (except for CD206) (Figure 
2A), accompanied by a slight increasing tendency of 
M1 markers (Supplementary information, Figure S2C), 
indicating that this cytokine is one of the main soluble 
factors present in the secretome of Mtb-infected macro-
phages responsible for the induction of M2-like mono-
cyte-macrophages.
The binding of IL-10 to its receptor leads to the subse-
quent activation of STAT3, whose role is essential for all 
known functions of IL-10 [36]. As shown in Figure 2B, 
short-term exposure of freshly isolated monocytes to cm-
MTB resulted in STAT3 phosphorylation on tyrosine 705, 
reflecting its activation. This activation was dependent 
on the presence of IL-10 since incubation of monocytes 
with IL-10-depleted cmMTB failed to trigger significant 
phosphorylation of STAT3 (Figure 2B). Next, we as-
sessed whether STAT3 was crucial for the establishment 
of M2-like monocyte-macrophages, using a siRNA-me-
diated gene silencing method [37], or pharmacological 
inhibition of STAT3 activation with either cucurbitacin I 
(CCB), which inhibits JAK2 (Janus kinase 2)-dependent 
phosphorylation of STAT3, or STATTIC, which targets 
the STAT3-SH2 domain thereby preventing its associ-
ation with upstream kinases. Both approaches enabled 
a nearly complete inhibition of STAT3 expression or 
phosphorylation in human monocyte-macrophages (Sup-
plementary information, Figure S3A-S3C). As expected, 
inhibition of STAT3 in cmMTB-treated cells reversed 
the acquisition of the CD16+CD163+MerTK+ phenotype, 
while CD206 or M1 marker expression remained unaf-
fected (Figure 2C and Supplementary information, Fig-
ure S3D-S3F). 
Altogether, the secretome of Mtb-infected mac-
rophages favors the human monocyte differentiation 
towards an M2-like activation program, which is main-
ly but not absolutely dependent (as best indicated by 
CD206 expression) on the IL-10/STAT3 axis. 
The CD16+ monocyte expansion is predisposed towards 
an M2-like phenotype in patients with active TB
Results obtained through our in vitro approach in-
ferred that the reported imbalance in circulating mono-
cyte subsets in TB patients might be associated with a 
predisposition towards a STAT3-driven M2-like pro-
gram. To address the physiological relevance of this 
issue, we analyzed in more detail the activation program 
of the circulating monocytes in TB patients. We col-
lected peripheral blood from healthy subjects (PB-HS), 
patients with active (PB-TB) or confirmed latent (PB-
LTB) TB (Supplementary information, Table S1), to 
evaluate the status of the CD14+ monocyte compartment. 
As previously described [18], we confirmed the higher 
proportion of CD16+ cells in PB-TB compared with PB-
HS, accounting for about 40% of the CD14+ monocytes 
(Figure 3A, Supplementary information, Figure S4A). 
Strikingly, the expansion of CD16+ monocytes is non-ex-
istent in PB-LTB, indicating that the abundance of these 
cells is associated with active TB (Figure 3A, Supple-
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mentary information, Figure S4B). While we failed to 
correlate the enhanced level of CD16 expression with the 
M2-like phenotype characterized in our in vitro model 
(Supplementary information, Figure S4B), freshly isolat-
Figure 2 The IL-10/STAT3 pathway drives the predisposition of CD16+ monocytes towards an M2-like phenotype. (A) Vertical 
scatter plots showing the MFI of cell-surface markers in monocytes cultured with IL-10-depleted cmMTB (cmMTBαIL-10) or 
the mock depletion control (cmMTBαIgG). (B) Immunoblot images of pY705-STAT3, STAT3 and actin (upper panel); quantifi-
cation of pY705-STAT3 versus STAT3 on monocytes after 1 h treatment with cmCTR, cmMTB, cmMTBαIL-10 or cmMTBαIgG 
(n = 6 donors; lower panel). (C) Vertical scatter plots showing the MFI of cell-surface markers in monocytes transfected with 
STAT3 (siSTAT3-black) or non-targeting control (siCTR-white) siRNAs, and conditioned with cmCTR or cmMTB. *P < 0.05, 
**P < 0.01, ***P < 0.001. Each circle within vertical scatter plots represents a single donor.
ed monocytes from TB patients displayed higher level of 
phosphorylated STAT3 compared with their counterparts 
from healthy subjects (HS), as measured by western 
blot analysis (Figure 3B). Using a flow cytometry-based 
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approach, we found that CD14+CD16+ can be differen-
tiated into two sub-populations according to the phos-
phorylation status of STAT3 (CD14+CD16+pSTAT3− and 
Figure 3 The CD16+ monocyte expansion is predisposed towards an M2-like phenotype in patients with active TB. (A) 
Vertical scatter plots showing the percentage of CD14+CD16+ cells in the peripheral blood of healthy subjects (PB-HS), TB 
patients (PB-TB) or subjects with latent TB (PB-LTB). (B) Immunoblot images of pY705-STAT3, STAT3 and actin (left), and 
quantification of pY705-STAT3 versus STAT3 (right) on monocytes from healthy subjects (HS) or TB patients (TB) (n = 5 
donors). (C) Vertical scatter plots showing the MFI of cell-surface markers in HS or TB monocyte-derived macrophages dif-
ferentiated in vitro for 7 days. (D) Analysis of soluble form of CD163 (sCD163) level in sera of TB patients according to dis-
ease severity, as compared with HS. (E) Vertical scatter plots showing the serum level of sCD163 in TB patients before and 
12 months after start of treatment (TB-M12), as compared with contact donors. (F) ROC (receiver operating characteristic) 
curve of sCD163 concentration in TB patients compared with HS. (G) ROC curve of sCD163 concentration in TB patients 
before versus after treatment (TB versus TB-M12). The red circle represents the optimal cut point. (H) Monocytes from HS 
were treated with pleural effusion (PE) from TB (PE-TB) or non-TB (PE-nonTB) patients, or culture medium. Representative 
images of western blot illustrating the expression of pY705-STAT3, STAT3 and actin (n = 3). (I) Vertical scatter plots showing 
the MFI of CD16, CD163 or MerTK on CD14+ monocytes present in PE-TB or PE-nonTB from patients. *P < 0.05; **P < 0.01; 
***P < 0.001. Each circle within vertical scatter plots represents a single donor. AUC, area under the curve.
CD14+CD16+pSTAT3+). In TB patients, the percentage of 
CD14+CD16+pSTAT3+ is significantly increased (37.5% 
± 11.2%) compared with control donors (13.2% ± 6.1%, 
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P < 0.01, n = 6). Moreover, when differentiated in vitro 
with M-CSF, blood monocytes from TB patients exhibit-
ed a CD163hiMerTKhiHLA-DRloCD86lo macrophage phe-
notype (Figure 3C, Supplementary information, Figure 
S4C). Together, these results point out a predisposition of 
the human monocyte compartment towards an M2-like 
program in the TB context.
We previously reported that the expansion of periph-
eral CD16+ monocytes correlates with disease severity of 
TB patients [18]. To further characterize the activation 
program of this expanded cell population, we then as-
sessed the M2-like phenotype of circulating monocytes 
isolated from patients with different clinical parameters 
to distinguish TB severity (Supplementary information, 
Table S2). Unlike CD163, we observed that the cell-sur-
face expression of MerTK is significantly augmented in 
the case of patients with an advanced degree of the dis-
ease and accentuated within the CD16+ monocyte subset 
(Supplementary information, Figure S4D-S4E). Given 
that membrane-bound CD163 and MerTK receptors are 
subjected to inflammation-driven shedding [38, 39], we 
hypothesized that chronic infection with Mtb may also 
lead to the shedding of these receptors from the surface 
of circulating monocytes, and thus increase the expres-
sion of soluble CD163 (sCD163) and MerTK (MerTK 
ectodomain: sMer) in the serum of TB patients. Aside 
from a single report describing the circulating sCD163 as 
a predictive value for patient survival [40], there is vir-
tually no information about this scavenger receptor and 
MerTK in the TB context. We thus evaluated the sera 
from pulmonary TB patients and revealed a progressive-
ly increasing trend in the levels of sCD163, particularly 
striking in cases with an advanced degree of the disease 
(Figure 3D). Next, to examine whether the soluble ex-
pression of this receptor is related to the presence of 
bacilli, we measured sCD163 serum concentration in 
TB patients before and after treatment (Supplementary 
information, Table S3). Noticeably, the TB-induced ex-
pression of sCD163 is decreased significantly after treat-
ment (Figure 3E). This was further supported by receiver 
operating characteristic (ROC) curve analysis showing 
the relationship between the sensitivity and specificity 
at any cutoff values for sCD163 (Figure 3F and 3G). 
For TB patients in relation to HS, the area under the 
ROC curve (AUC) value for sCD163 was 0.78 (± 0.04) 
with a 95% confidence interval (CI) of 0.69 to 0.86 (P < 
0.0001), with an optimal cut point yielding a sensitivity 
of 84.8% and specificity of 58.9% (Figure 3F). For TB 
patients, before treatment in relation to the same cases 
after 12-month treatment (TB-M12), the AUC value for 
sCD163 was 0.76 (± 0.07) with a CI of 0.61 to 0.90 (P < 
0.001), with an optimal cut point providing a sensitivity 
of 84% and specificity of 52% (Figure 3G). In the case 
for sMer, however, we found no evidence supporting 
its shedding in TB (Supplementary information, Figure 
S4F-S4I). These results indicate that altered serum levels 
of sCD163 might be of potential use as a non-invasive 
biomarker for pulmonary TB disease progression and 
monitoring of treatment efficacy.
To further explore the association between Mtb in-
fection and the alteration of the human monocyte com-
partment, we obtained pleural effusion fluids from TB 
patients (PE-TB) and other non-TB-related infectious 
diseases (PE-nonTB; Supplementary information, Table 
S1). As PE-TB is the most common form of extrapulmo-
nary TB, we tested its capacity to influence the activation 
program of freshly isolated monocytes from HS, and 
noticed that both PE-TB and PE-nonTB were able to in-
duce a rapid phosphorylation of STAT3 (Figure 3H). Im-
portantly, when assessing the CD14+ population isolated 
directly from PE-TB, we observed that these cells tend to 
display a higher acquisition of the CD16+CD163+MerTK+ 
phenotype in comparison with their counterparts from 
PE-nonTB (Figure 3I), suggesting that an Mtb-derived 
microenvironment influences the human monocyte com-
partment via STAT3.
The abundance of the CD16+CD163+MerTK+pSTAT3+ 
cell population correlates with pathology severity in 
non-human primate pulmonary TB
Pulmonary granuloma formation is a hallmark of TB, 
and the activation program of monocyte-macrophages 
is thought to play an important role in this process [41]. 
Therefore, we further investigated whether the M2-like 
CD16+CD163+MerTK+ cell population is present in pul-
monary granulomas of Mtb-infected NHPs. The NHP tis-
sue samples were derived from BCG (Bacillus Calmette-
Guérin) vaccinated and unvaccinated Mtb-infected 
rhesus macaques, exhibiting different degrees of lung 
pathology that was in general inversely correlated with 
time to end point (survival; Supplementary information, 
Figure S5A). Immunohistochemical analyses revealed 
that macrophage infiltration (CD68+) increased according 
to lung pathology severity (Figure 4A, Supplementary 
information, Figure S5B); this pattern was also accom-
panied by increased CD163 expression in tuberculous 
granulomas in NHPs (Figure 4A, Supplementary infor-
mation, Figure S5B) [42]. Concomitantly, we observed 
an elevated expression of CD16 and MerTK in NHP tu-
berculous granulomas (Figure 4A, Supplementary infor-
mation, Figure S5B). Notably, the expression of CD163, 
CD16 and MerTK positively correlated with the severity 
of lung pathology (Figure 4B). Co-localization analysis 
within CD163+ macrophages revealed that CD16 and 
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Figure 4 The abundance of the CD16+CD163+MerTK+pSTAT3+ cell population correlates with pathology severity in non-hu-
man primate (NHP) pulmonary TB. (A) Representative immunohistochemical images demonstrate expression and distribution 
of CD68, CD16, CD163 and MerTK in lung granulomas from non-vaccinated Mtb-infected NHPs exhibiting different severity 
of pulmonary TB. NHP numbers refer to Supplementary information, Table S6. (B) Correlation analysis between the number 
of CD16+, CD163+ or MerTK+ cells in lung tissue and lung pathology score in BCG-vaccinated (red circles) or -non-vaccinated 
(black circles) Mtb-infected NHPs. (C, D) Immunohistochemistry stainings of lung biopsies from NHP n°51 (intermediate). (C) 
Upper panel: co-localization of CD163 (green; Alexa-488) and CD16 (red; Alexa-555) in lung tissue; lower panel: co-local-
ization of CD163 (green; Alexa-488) and MerTK (red; Alexa-555) in lung tissue. White arrows indicate double-positive cells 
that are magnified in 1 and 2 (inset scale bar = 10 µm). (D) Upper panel: nuclear localization of STAT3 (green; Alexa-488) in 
CD16 (red; Alexa-555)-positive cells in lung tissue; lower panel: nuclear localization of STAT3 (green; Alexa-488) in CD163 (red; 
Alexa-555)-positive cells in lung tissue. White arrows indicate CD16- or CD163-positive cells with STAT3 translocated in the 
nucleus stained with DAPI (blue; inset scale bar = 10 µm).
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MerTK were co-expressed in this population (Figure 
4C). Even though phosphorylated STAT3 could not be 
assessed in the NHP samples due to technical reasons, 
we did observe accumulation of STAT3 in the nuclear 
area of CD163+ and CD16+ cell populations, indicating 
that this transcription factor is activated in these leuko-
cytes (Figure 4D).
Collectively, these results suggest that the environment 
created during pulmonary TB is capable to modulating 
macrophage activation into an M2-like program, which 
becomes accentuated according to disease severity.
The CD16+CD163+MerTK+pSTAT3+ monocyte-macro-
phages display an efficient ability to migrate in dense 
matrices
To determine whether the expansion of the M2-like 
monocyte-macrophages is beneficial or detrimental to 
host defense against TB, we investigated functional con-
sequences of this activation program. Studies performed 
in zebrafish model showed that the environment induced 
by mycobacterial infection stimulates the recruitment of 
highly motile macrophages in a matrix metalloproteases 
(MMP)-dependent manner, which is known to enhance 
the pathogenesis [43, 44]. On the basis of these obser-
vations, we investigated whether cmMTB influences 
human monocyte-macrophages migration in different 3D 
environments that mimic tissues [45]. Cell migration was 
first analyzed in dense Matrigel in which protease-me-
diated matrix digestion is mandatory for macrophage 
infiltration, in contrast to protease-independent migration 
in porous fibrillar collagen I matrices [45]. In Matrigel, 
when cmMTB was used as chemoattractant, the migra-
tion of human monocyte-macrophages into this matrix 
was enhanced and the distance covered by the cells was 
increased (Figure 5A, Supplementary information, Fig-
ure S6A). Similar results were obtained using another 
Figure 5 The CD16+CD163+MerTK+pSTAT3+ monocyte-macrophages display a strong ability to migrate in dense matrices. 
(A) Human monocytes were seeded on the top of fibrillar collagen I or Matrigel matrices, and allowed to migrate in response 
to cmCTR (white) or cmMTB (black). Quantification of the percentage of migrating cells (n = 7 donors). (B) Effect of protease 
(Pimix), matrix metalloprotease (GM6001), Rho-associated kinase (Y27632) inhibitors or DMSO on cell migration in Matrigel 
(n = 9 donors). (C) Representative scanning electron microscopy images showing the matrix remodeling activity of cells on 
Matrigel (n = 3 donors, scale bar = 10 µm). (D) Quantification of gelatin zymogram gels for MMP9 (left) and MMP1 (right) 
activities (n > 4 donors). (E) Monocytes transfected with SMARTpool targeting STAT3 (siSTAT3) or non-targeting control siR-
NAs (siCTR) were seeded on Matrigel and allowed to migrate in response to cmMTB (n = 3 donors). (F) Monocytes from HS 
were seeded on Matrigel and allowed to migrate in response to PE-TB, PE-nonTB or culture medium (n = 3 donors). Results 
are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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dense matrix such as gelled collagen I, strengthening the 
use of protease activity during cmMTB-induced migra-
tion (Supplementary information, Figure S6B). In con-
trast, cells infiltrated the porous fibrillar collagen I matrix 
efficiently regardless of the provided chemoattractant, 
cmMTB or cmCTR (Figure 5A). We showed in the past 
that macrophage 3D migration in dense matrices depends 
on both protease activity and the tyrosine kinase Hck, 
but not the ROCK kinase pathway [37, 45-47]. In line 
with these previous findings, both a cocktail of protease 
inhibitors (Pimix) and the broad-spectrum MMP inhibi-
tor GM6001 abrogated the cmMTB-enhanced migration 
into Matrigel (Figure 5B). Moreover, this process was 
also partially inhibited by siRNA-mediated silencing of 
Hck in these cells (Supplementary information, Figure 
S6C). As expected, the use of a ROCK kinase inhibitor 
(Y27632) had no effect on the cmMTB-enhanced motili-
ty in Matrigel (Figure 5B). To further support the role of 
MMP in the monocyte-macrophage migration, we per-
formed scanning electron microscopy. Our observations 
revealed that in response to cmMTB, cells profoundly re-
modeled the matrix compared with those treated with the 
cmCTR or the MMP inhibitor (Figure 5C). Interestingly, 
while MMP1 and MMP9 activities were increased in the 
culture medium of cmMTB-treated cells (Figure 5D), the 
MMP2 activity was unchanged (Supplementary informa-
tion, Figure S6D), alluding to the selectivity of MMPs in 
cmMTB-enhanced motility. 
Next, we investigated which soluble factor in cmMTB 
induces monocyte 3D migration in Matrigel. In zebrafish 
and mouse models, the chemokine C-C motif ligand-2 
(CCL2)-dependent recruitment of CCR2+ macrophages 
plays a critical role in the mycobacterial pathogenesis 
[44, 48]. Here we found that migration in Matrigel is 
mainly based on chemoattraction mediated by recom-
binant CCL5 but not CCL2 or CCL4 (Supplementary 
information, Figure S6E). Despite the fact that the ex-
pression of CCR2 and CCR5 was enhanced by cmMTB 
(Supplementary information, Figure S1C), and that 
their different chemokine ligands are strongly secreted 
by Mtb-infected macrophages [29, 34], the depletion of 
CCL2, CCL4 and CCL5 from cmMTB did not signifi-
cantly alter their migration properties (Supplementary 
information, Figure S6F). Since the activation program 
of macrophages modulates their 3D migration capacities 
[49], we hypothesized that the enhanced cell motility in 
response to cmMTB might result from the acquisition of 
the M2-like phenotype. To explore this possibility, we 
first conditioned freshly isolated monocytes with cmCTR 
or cmMTB, and then tested their migration capacity in 
Matrigel without a specific chemoattractant. Compared 
with cmCTR-treated cells, those treated with cmMTB 
Figure 6 The CD16+CD163+MerTK+pSTAT3+ monocyte-mac-
rophages are associated with a permissive phenotype to Mtb 
infection. (A) Representative confocal microscopy images of 
CD16+ cells (red, Alexa-555) in lung granulomas from NHP 
N°51 infected by Mtb (green, Alexa-488). White arrow indicates 
CD16+ cells containing Mtb bacilli (inset, scale bar = 10 µm). (B) 
Monocytes conditioned with cmCTR (white circles) or cmMTB 
(black circles) were infected with Mtb. On day 0 and day 5 after 
infection, the intracellular growth of Mtb was scored by colo-
ny-forming unit (CFU) assay. (C) Monocytes transfected with 
SMARTpool targeting STAT3 (siSTAT3) or non-targeting control 
siRNAs (siCTR) were conditioned with cmMTB, and then infect-
ed with Mtb. The CFU scoring was measured on day 0 and day 
5 after infection. Results are expressed as before-and-after plot; 
*P < 0.05.
efficiently infiltrated and remodeled Matrigel (Supple-
mentary information, Figure S6G), indicating that acqui-
sition of the M2-like phenotype is sufficient to enhance 
3D migration regardless of a chemoattractant gradient. 
Furthermore, the Mtb-derived bystander effect can be 
mimicked when monocytes were conditioned with re-
cIL-10 (Supplementary information, Figure S6H-S6I). 
Consistently, when STAT3 expression was inhibited in 
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these cells, or IL-10 was depleted from cmMTB, the pro-
tease-dependent migratory capacity of conditioned cells 
was impaired (Figure 5E, Supplementary information, 
Figure S6I).
Since the monocyte-macrophages characterized by 
the CD16+CD163+MerTK+ signature are abundant in the 
TB pleural cavity, we assessed whether PE-TB fluid ac-
tivates the motility of these cells. For these experiments, 
we used non-TB pleural fluid (PE-nonTB) as a positive 
control since it is known to activate STAT3 and serve a 
chemoattractant [50]. As illustrated in Figure 5F, fresh-
ly isolated monocytes from healthy donors displayed a 
greater capacity to infiltrate Matrigel when PE-TB and 
PE-nonTB were used as chemoattractants.
Taken together, our analysis shows that the acquisition 
of CD16+CD163+MerTK+pSTAT3+ activation program 
via the IL-10/STAT3 axis triggers MMP-dependent mo-
tility and allows human monocytes to penetrate and re-
model dense tissue environments.
The CD16+CD163+MerTK+pSTAT3+ monocyte-macro-
phages are associated with a permissive phenotype to 
Mtb infection
The migration of mononuclear phagocytes towards in-
fectious sites is essential for effective control and clear-
ance of bacteria [51]. First, we observed that, among oth-
er cell types, CD16+ cells in NHP tuberculous granulo-
mas contained bacilli, implying that these leukocytes can 
be infected in vivo (Figure 6A). Since M2 macrophages 
are associated with pathogen permissivity [3], we evalu-
ated the ability of monocytes conditioned with cmMTB 
or cmCTR, and then infected with Mtb, to control bacilli 
growth. CFU scoring at four hours post infection (p.i.) 
revealed that there was no difference in the bacterial 
loads present in cmCTR- and cmMTB-treated cells, sug-
gesting that soluble factors present in cmMTB do not af-
fect the recognition and uptake of the bacilli (Figure 6B). 
However, cmMTB-treated cells were significantly more 
permissive to Mtb growth than cmCTR-treated cells, as 
illustrated at day 5 p.i. (Figure 6B). Inhibition of STAT3 
by siRNA-mediated gene silencing in cmMTB-treated 
cells reversed their pathogen-permissive phenotype (Fig-
ure 6C, Supplementary information, Figure S7A). Simi-
lar results were obtained by an alternative approach using 
the pharmacological inhibition of STAT3 activation with 
STATTIC (Supplementary information, Figure S7B).
Collectively, these results show that the CD16+C-
D163+MerTK+pSTAT3+ activation program acquisition 
renders human monocyte-macrophages more susceptible 
to intracellular bacterial growth.
The CD16+CD163+MerTK+pSTAT3+ monocyte-macro-
phages display immuno-modulatory properties
M2 macrophages programmed with IL-10, TGFβ or 
glucocorticoids are known as “deactivators” of the im-
mune response [28]. Among the features that distinguish 
these cells is the low production of pro-inflammatory 
cytokines (e.g., TNFα and IL-12), contrasting with high 
expression of anti-inflammatory mediators (e.g., IL-10, 
TGFβ and Gas6) [28, 39]. We first assessed the ability 
of cmMTB-conditioned cells to engage production of 
inflammatory signals in response to killed Mtb, in order 
to discriminate the well-described suppressive effects 
using live Mtb [4]. Our results indicate that, compared 
with cells treated with cmCTR, those conditioned with 
cmMTB expressed less pro-inflammatory genes, such as 
TNF, IL12A and CCL1 (Supplementary information, Fig-
ure S8A). The reduced secretion of TNFα was confirmed 
in the supernatant of cmMTB-treated cells (Supplemen-
tary information, Figure S8B). Strikingly, a weaker ex-
pression of IL-10 was observed in contrast to the elevated 
level of GAS6 and PROS1, in cells pretreated with cm-
MTB (Supplementary information, Figure S8A). Another 
feature that distinguishes deactivator macrophages is the 
poor ability to activate T cells [28]. To evaluate this, we 
first examined the programmed death ligand 1 (PD-L1) 
expression relative to that of CD86, since an increased 
PD-L1/CD86 ratio in mononuclear phagocytes is report-
ed to inhibit T cell proliferation and interferon-gamma 
(IFNγ) production [52]. Noticeably, we found that the 
PD-L1/CD86 ratio was highly elevated in cmMTB-con-
ditioned cells compared with cmCTR treatment (Figure 
7A, Supplementary information, Figure S8C). Stimula-
tion with killed Mtb did not change this unbalanced ratio 
in cmMTB-conditioned cells (Figure 7A, Supplementary 
information, Figure S8C). Next, we measured the capac-
ity of cmMTB-conditioned monocyte-macrophages to 
activate allogeneic human T cells, using peripheral blood 
lymphocytes labeled with CFSE. Importantly, the cm-
MTB-conditioned cells displayed a significantly lower 
capacity to stimulate T cell proliferation and IFNγ pro-
duction in comparison with cmCTR-treated cells (Figure 
7A). While we only observed a tendency towards the 
reversion of the unbalanced PD-L1/CD86 ratio (Figure 
7B), the inhibition of STAT3 phosphorylation with cu-
curbitacin significantly reverted the cell surface expres-
sion of PD-L1 in cmMTB-treated cells and their poor ca-
pacity to activate T cells (Figure 7B and Supplementary 
information, Figure S8D). To validate these observations 
in vivo, we examined whether monocyte-macrophages 
in TB patients display immunomodulatory properties. 
As shown in Figure 7C, upon stimulation with killed 
Mtb, monocytes from PB-TB displayed an elevated PD-
L1/CD86 ratio compared with those from PB-HS. In 
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addition, PB-TB monocytes exhibited a lower ability to 
induce T cell proliferation and the production of IFNγ 
in allogeneic T cells compared with PB-HS monocytes 
(Figure 7C).
Taken together, these data demonstrate that the acqui-
sition of the CD16+CD163+MerTK+pSTAT3+ activation 
program is characterized by a (i) low ratio of pro-/an-
ti-inflammatory factor production, (ii) high ratio of PD-
L1/CD86 co-stimulatory molecule expression and (iii) 
poor capacity to activate T cells, which indicates a nega-
tive contribution to a dedicated host response against TB.
Discussion
TB mortality is unacceptably high given that most 
deaths are preventable. The identification of new bio-
Figure 7 The CD16+CD163+MerTK+pSTAT3+ monocyte-macrophages display immunomodulatory properties. (A-C) Mono-
cytes were stimulated with killed Mtb or PBS (mock). Top panels: vertical scatter plots showing the ratio of MFI obtained for 
PD-L1 and CD86. Results are expressed as mean ± SEM. Bottom panels: allogeneic human T lymphocytes labeled with 
CFSE were co-cultured with monocytes. Before-and-after plots showing T cell proliferation illustrated as the percentage of 
CFSE-dividing cells (left) and the production of IFNγ by proliferating T cells quantified by (A-B) ELISA in co-culture superna-
tants or (C) flow cytometry (right). (A) cmCTR- or cmMTB-conditioned monocytes were stimulated with PFA-killed Mtb or PBS 
(mock). (B) cmMTB conditioning of monocytes was performed in the presence of the STAT3 inhibitor, cucurbitacin I (CCB) or 
DMSO as control. Cells were then stimulated with PFA-killed Mtb or mock. (C) Monocytes from HS or TB patients were stim-
ulated with irradiated Mtb or mock. *P < 0.05; **P < 0.01. Each circle within vertical scatter plots represents a single donor.
markers that could reduce the size and duration of clin-
ical trials of new drug candidates and define treatment 
efficacy, disease activity, cure and relapse, is highly 
desirable to reduce the impact of TB. Considering that 
the monocyte compartment is perturbed in TB, we asked 
whether this shift is beneficial or detrimental to host 
defense against TB, and whether this could represent a 
target for treatment. We believe that this study makes 
four major contributions to the interface between hypoth-
esis-driven basic research and the identification of po-
tential bio-signatures and molecular markers for human 
disease (Figure 8). 
First, we present evidence for how human monocytes 
are predisposed in the context of TB towards an anti-in-
flammatory M2-like (CD16+CD163+MerTK+pSTAT3+) 
macrophage activation program, a process that is mainly 
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dependent on the IL-10/STAT3 signaling pathway. This 
phenotype can also be obtained in vitro using the secre-
tome of Mtb-infected macrophages. We provide a new 
set of markers to characterize this M2-like activation 
program in terms of hallmark cell-surface markers (i.e., 
CD16+, CD163+ and MerTK+), the transcription factor 
STAT3, cytokine content (e.g., TNFαlow), chemokines 
receptors (i.e., CCR2high and CCR5high), co-stimulatory 
molecules (i.e., PD-L1high and CD86low) and MMP (i.e., 
MMP1high and MMP9high). Interestingly, we also detected 
CD206 expression as part of the described M2-like phe-
notype, which was independent of the IL-10/STAT3 axis. 
Since CD206 is known to be dependent of STAT6 signal-
ing [53], it is probable that alternative signals (e.g., IL-
Figure 8 Model illustrating how the environment induced by Mtb infection predisposes human monocyte differentiation to-
wards an M2-like macrophage, altering host defense during infection. Alveolar macrophages are one of the first leukocytes 
able to recognize and phagocytose Mtb upon entry in the respiratory system. At this site, infected macrophages reshape 
their microenvironment by secreting many soluble factors including cytokines and chemokines, which for the most part are 
responsible for the leukocyte infiltration during the earliest stages of infection. However, (1) Mtb has the capacity to modulate 
the macrophage response and to induce the secretion of anti-inflammatory cytokines, such as IL-10. IL-10, tilts, through a by-
stander effect, monocytes towards an M2-like macrophage program (CD16+CD163+MerTK+pSTAT3+) in a STAT3-dependent 
manner. In the blood, CD163 and MerTK receptors are cleaved off, and concentration of their soluble form correlates positive-
ly with disease severity. The CD16+CD163+MerTK+pSTAT3+ phenotype acquisition is accompanied by (2) an enhanced pro-
tease-dependent motility through matrix metalloprotease activity (e.g., MMP-1), which allows extracellular matrix remodeling, 
and hypothetically, trans-tissular migration. This phenotype acquisition also renders (3) monocyte-macrophages permissive to 
Mtb intracellular growth, and (4) immunomodulatory in terms of their reduced ability to secrete pro-inflammatory cytokines (e.g., 
low TNFα) and activate the T-helper 1 (Th1) response via co-stimulatory signaling (e.g., high ratio PD-L1/CD86). Collectively, 
the Mtb-derived bystander activation of STAT3 in monocytes predisposes their differentiation program towards a macrophage 
population that ultimately shifts the microenvironment (e.g., tuberculous granulomas) in favor of microbial resilience in the 
host.
2, IL-15 and IFNα), which are part of the secretome of 
Mtb-infected macrophages, are partially responsible for 
the establishment of this M2-like phenotype. Neverthe-
less, in our in vitro model, the blocking of IL-10 in the 
Mtb-derived conditioned media seems to be sufficient to 
impair STAT3 activation and the establishment of M2-
like phenotype. This is in line with the fact that IL-10 is 
considered to be an important clinical biomarker of dis-
ease progression [54], increased levels for this cytokine 
are reported in both the blood [31, 55] and in the bron-
choalveolar lavage of active TB patients [56], and in the 
tuberculous granuloma context in NHP model [57]. The 
fact that we observed elevated levels of activated STAT3 
in monocyte-macrophages in both TB patients and in the 
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NHP tuberculous granuloma context, suggests that over-
active production of IL-10 may be responsible. It remains 
to be seen whether activation of STAT3 by other signals, 
such as IL-6 or IL-27, generates a similar activation pro-
gram with critical consequences for TB pathogenesis and 
other chronic inflammatory diseases.
Second, mainly based on our in vitro approach, we 
characterized key functional properties for the human 
CD16+CD163+MerTK+pSTAT3+ monocyte-macrophages. 
To begin, we provided evidence that these cells display 
an enhanced capacity to migrate through dense matri-
ces in an MMP-dependent manner contrasting with our 
previous observations that 3D migration in dense ma-
trices rather involves cathepsins [45, 47, 58, 59]. While 
we cannot exclude that chemokines present in cmMTB 
could be involved in the migration capacity of CD16+C-
D163+MerTK+pSTAT3+ monocyte-macrophages, we 
showed that STAT3-dependent acquisition of the M2-
like phenotype is essential for the enhanced motility and 
extracellular matrix remodeling activity in these cells. 
This process is accompanied by MMP1 and MMP9 
activity that may contribute to lung tissue damage and 
TB pathogenesis, as suggested by the formation of pro-
tease-mediated tunnels in 3D matrices [47, 60, 61], by a 
study demonstrating that MMP1 is increased during Mtb 
infection and is responsible for lung immunopathology 
[62], and by other reports evidencing the role of MMP9 
in the recruitment of macrophages, granuloma matura-
tion and bacterial dissemination [44]. This is an exciting 
finding given that, in the zebrafish and mouse models, 
mycobacteria infection recruits highly motile macro-
phages as a tool for bacterial dissemination [44, 48]. An-
other functional characteristic described in this study is 
the permissive nature of CD16+CD163+MerTK+pSTAT3+ 
cells to handle Mtb intracellular growth. To our knowl-
edge, our study is the first to demonstrate that abrogation 
of STAT3 in monocyte-macrophages restores the control 
of Mtb intracellular growth. Actually, STAT3 has been 
shown to block phagolysosome fusion, induction of au-
tophagy, and optimal release of nitric oxide and reactive 
oxygen species [63]. However, the regulation of these 
microbicidal activities by STAT3 has yet to be explored 
for TB [63]. This is in line with the antagonistic effect 
of IL-10 on microbicidal activities of Mtb-infected mac-
rophages, such as phagosome-lysosome fusion [63, 64], 
and IFNγ-induced production of oxygen and nitrogen 
species [65]. Likewise, mice overexpressing IL-10 spe-
cifically in the macrophage compartment present suscep-
tibility to Mtb infection due to macrophages displaying 
an exaggerated M2-like activation program associated 
with a high pulmonary bacterial load [66]. In parallel, we 
also demonstrate that CD16+CD163+MerTK+pSTAT3+ 
monocyte-macrophages display an immunomodulatory 
functional capacity. Besides the diminished pro-inflam-
matory cytokine response, CD16+CD163+MerTK+p-
STAT3+ cells also display a high PD-L1 to CD86 ratio 
and tolerant capacity to control T cell activation. This is 
in accordance with different reports showing that STAT3 
is a key anti-inflammatory mediator that inhibits import-
ant pro-inflammatory processes [36, 63]. For instance, 
mice deficient for the IL-27 receptor (a STAT3 activator) 
exhibited an uncontrolled production of pro-inflammato-
ry cytokines, elevated levels of IFNγ-producing T cells, 
enhanced macrophage effector functions and reduced 
bacterial loads, in response to Mtb infection. Yet, these 
animals eventually succumb to uncontrolled immunopa-
thology [67]. In a reciprocal case, a mouse with targeted 
deletion in the myeloid compartment for the suppressor 
of cytokine signaling-3 (SOCS3), which is known to 
inhibit STAT3, showed increased susceptibility to Mtb 
infection [68]. On the basis of these functional observa-
tions, our study provides an original biological context 
to further understand at the molecular level how STAT3 
activity grants protease-dependent migration capacity 
and inhibits antimycobacterial effector mechanisms, 
consequently opening up new venues to investigate 
how it might contribute to tissue remodeling, pathogen 
dissemination and immunomodulation. Beyond the im-
munomodulatory capacity (Figure 7C), it remains to be 
shown whether this IL-10/STAT3-dependent functional 
program is truly established during the expansion of 
CD16+CD163+MerTK+pSTAT3+ monocyte-macrophages 
in patients with active TB.
The third major contribution from this study concerns 
the critical correlation of the abundance of CD16+C-
D163+MerTK+pSTAT3+ monocyte-macrophages with the 
severity of TB disease in the human and NHP contexts. 
Recent studies by Zizzo et al. [25, 69] suggested a strict 
correlation between systemic lupus erythematosus (SLE) 
disease severity and the activation of an M2-like macro-
phage characterized by CD163 and MerTK expression 
during the monocyte-to-macrophage differentiation. 
Expanding upon our previous observation that the mono-
cyte compartment becomes perturbed in TB patients [18], 
we now report that the CD163+MerTK+pSTAT3+ sig-
nature accompanies the expansion of the CD16+ mono-
cytes. As these results contrast with the pro-inflammatory 
phenotype of CD16+ monocytes in healthy donors [13, 
15-17], we infer that all CD16+ monocytes are not cre-
ated in a similar manner, and thus the CD16 expression 
in monocyte-macrophages cannot be extrapolated to 
indicate a pro- or anti-inflammatory nature. Their final 
differentiation program might result as a consequence of 
the microenvironment shaped in health and disease pro-
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gression contexts. In agreement with a recent description 
of CD163+ macrophages during the onset of tuberculous 
pleurisy [70], we show that this M2-like macrophage is 
particularly enriched within the CD14+CD16+ cell pop-
ulation isolated from the pleural cavity of TB patients. 
Considering that the CD16+ population expansion dis-
plays an M2-like phenotype in the pleural cavity from TB 
patients, and that TB pleural effusion activates STAT3 
phosphorylation in monocytes from healthy donors and 
stimulates their protease-dependent migration, we infer 
that the environmental signals within Mtb infection sites 
perpetuate the CD16+CD163+MerTK+pSTAT3+ activation 
program and possibly also serve as chemoattractant. At 
the tissue level, although there are key reports integrating 
the concept of macrophage activation within tuberculous 
granulomas [41, 42], to our knowledge this is the first 
study to identify the CD16+CD163+MerTK+ macrophage 
activation program along with the co-localization of ac-
tivated STAT3. Beyond the detection of CD163, we now 
provide a novel marker signature composed of CD16, 
MerTK and activated STAT3, which could be helpful to 
identify the anti-inflammatory and immunomodulatory 
macrophage program in the progression of TB disease. 
Based on the known inhibitory role for IL-10 in the 
formation of protective mature granulomas during Mtb 
infection [63, 71], the presence of these cells may rep-
resent a cellular indicator of granulomas that foment the 
expansion and dissemination of disease [41, 44]. Indeed, 
human CD16+CD163+MerTK+pSTAT3+ macrophages 
meet the criteria for the formation of pathogenic granu-
lomas mainly described in the zebrafish model: secretion 
of MMPs involved in granuloma formation (i.e., MMP1 
and MMP9), high protease-dependent motility, pathogen 
permissiveness and immunomodulatory capacity to regu-
late a pro-inflammatory environment [44]. For example, 
the monocyte predisposition towards M2-like macro-
phage program alters protective granuloma formation 
during Schistosoma mansoni infection, which indicates a 
general process contributing to granulomatous diseases 
[72]. On the basis of these observations, we propose that 
the unbalanced monocyte compartment in TB is predis-
posed to differentiate towards the anti-inflammatory M2-
like macrophages as a continuously failed attempt by 
the host to limit immunopathology, whose abundance is 
directly related to the severity of TB disease, ultimately 
contributing to the establishment of chronic infection.
The last major contribution of this study is the iden-
tification of soluble form of CD163 as a potential bio-
marker to monitor, in combination with actual and next 
to be discovered biomarkers, TB disease progression and 
anti-TB treatment efficacy. Unlike the CD14+CD16+ cell 
population found in the pleural cavity, we failed to detect 
CD163 as part of the cell-surface marker signature in cir-
culating monocytes in TB patients. This was an intrigu-
ing observation as circulating monocytes from TB pa-
tients still displayed high level of phosphorylated STAT3 
and immunomodulatory potential in terms of high PD-L1 
to CD86 expression ratio along with a poor capacity to 
activate allogeneic T cells. The detection of sCD163 in 
TB patients reconciled these observations, as monocytes 
are the only circulating cell population known to express 
CD163 and MerTK [38, 73]. Indeed, the plasma level of 
these soluble receptors correlated with TB disease sever-
ity in patients, and upon anti-TB treatment, it significant-
ly decreased to the plasma concentration level obtained 
from contact individuals. As sCD163 shows optimal 
sensitivity and specificity according to the ROC analysis 
provided in the TB context, we thus propose this soluble 
receptor, in combination with actual diagnosis tools and 
next to be discovered molecules, as a potential biomarker 
to evaluate disease progression and predict drug treat-
ment outcome. In a second step, these results need to be 
confirmed in a larger cohort of individuals from differ-
ent genetic background. Indeed, there is only one study 
that correlated the plasma concentration of sCD163 to 
the survival of verified TB patients [40]. However, there 
has been no confirmation of these results ever since, and 
more importantly, there is no actual evaluation available 
on the effect of anti-TB drugs on sCD163 levels until 
now. Interestingly, sCD163 is considered as a valuable 
marker of the activation of an M2-like monocyte-macro-
phage program and biomarkers of disease activity in SLE 
[25, 40], alluding to a critical biological significance for 
the presence of this soluble receptor as immune response 
biomarkers in TB disease. 
In conclusion, our study provides a novel cellular 
context, along with identification of molecules and path-
ways, which may fuel new research venues concerning 
monocyte-macrophages in the TB context. Newly rec-
ommended guidelines for the nomenclature of the mac-
rophage activation process are based on three principles: 
source of macrophages, definition of activators and a 
consensus collection of markers to describe macrophage 
activation [23]. On the basis of these guidelines, the hu-
man CD16+CD163+MerTK+pSTAT3+ activation program 
described in this study within the TB context is reason-
ably related to the proposed “M(IL-10)” nomenclature. 
However, in a pathological context, multiple signals can 
activate STAT3-dependent signaling pathways (e.g., IL-
6, IL-23 and IL-27) [36, 63]. Consequently, it remains to 
be determined whether they activate STAT3 in a similar 
fashion as IL-10 to specifically establish the TB-asso-
ciated CD16+CD163+MerTK+pSTAT3+ phenotype and 
functional profile reported in this study; if so, the no-
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menclature “M(STAT3)” would be a way to subsume the 
phenotype and functions of cells belonging to STAT3-de-
pendent activation program(s). Interestingly, global 
biomarker studies are sometimes criticized as being 
non-hypothesis driven [2]. We believe that the functional 
characterization of this M(IL-10)-like program, and its 
critical in vivo assessment in TB patients and NHP tuber-
culous granulomas, adds a significant pathological con-
text to the biomarker potential of sCD163. Finally, since 
immune impairment is usually observed in patients with 
chronic infections, and given that the STAT3 activity 
grants a tolerance capacity to the myeloid compartment 
[36], we estimate that short-term blockade of STAT3 
within the monocyte-to-macrophage differentiation 
program has the potential to modulate mechanisms of 
disease tolerance and restore the antimicrobial immunity. 
STAT3 inhibitors, currently assessed in phase I clinical 
trials for their antitumor effects [74, 75], might be partic-
ularly useful in patients with TB meningitis, for example, 
who fail to control mycobacterial proliferation because 
of intrinsic exacerbation of immune suppression, and in 
which dexamethasone treatment has deleterious effects 
[76].
Materials and Methods
Human and NHP samples
Studies involving human samples from healthy donors and TB 
patients, and samples from NHPs were performed in accordance to 
guidelines approved by all indicated Ethical committees; see Sup-
plementary information, Data S1.
Preparation of human monocytes and monocyte-derived 
macrophages
Monocytes from healthy donors and from TB patients were iso-
lated by CD14 positive magnetic labeling and differentiated into 
macrophages as previously described [18, 37, 45]; see Supplemen-
tary information, Data S1. 
Preparation of conditioned media and monocyte treatment
The cmMTB medium was prepared from Mtb-infected mono-
cyte-derived macrophages at a multiplicity of infection (MOI) of 
three bacteria per cell, in RPMI 1640 (Gibco) containing 10% FBS 
(Sigma-Aldrich). The cmCTR medium was obtained from unin-
fected macrophages. After overnight incubation at 37 °C, culture 
media were collected, sterilized by filtration and aliquots were 
stored at −80 °C. For conditioning, human CD14+ sorted mono-
cytes were allowed to adhere for 1 h on glass coverslips in the ab-
sence of serum and then cultured for 3 days with 50% dilution of 
cmMTB or cmCTR containing M-CSF (Peprotech, 10 ng/ml) and 
10% FBS. Cell surface expression of macrophage activation mark-
ers (Supplementary information, Table S4), and bacterial intracel-
lular growth, were measured using standard procedures detailed in 
Supplementary information, Data S1.
3D migration assays
3D migration assays were performed as previously described 
[45]. Briefly, fibrillar collagen I, gelled collagen I or Matrigel was 
polymerized in transwell inserts and used immediately. Cells were 
seeded on top of matrices, the lower chamber of each insert was 
filled with a 50% dilution of cmMTB or cmCTR in complete me-
dium or with complete medium supplemented with recIL-10. Cell 
migration into fibrillar collagen I was quantified after 24 h, where-
as the migration in dense matrices (Matrigel or gelled collagen I) 
was quantified after 72 h. The percentage of cell migration was 
obtained as the ratio of cells within the matrix to the total number 
of counted cells as described [45].
Assessment of the inflammatory cytokine response and acti-
vation of T cells
Total RNAs were reverse transcribed and amplified as detailed 
in Supplementary information, Data S1. Primers for qPCR are 
listed in Supplementary information, Table S5. The mRNA content 
was normalized to the metastatic lymph node protein 51 (MLN51) 
mRNA and quantified using the ∆∆Ct method. Secreted TNFα  and 
IL-10 were measured by ELISA. Activation of allogeneic T cells 
was evaluated in mixed lymphocyte reactions including cell prolif-
eration by flow cytometry and secreted IFNγ analysis by ELISA or 
flow cytometry.
Plasma biomarker measurements
Concentrations of soluble sCD163 and sMer (R&D system 
DuoSet) were assessed in cryopreserved human serum samples 
maintained at −80 °C, according to the manufacturer’s instruction. 
For sCD163 analysis, the serum was diluted at 1/10, and for sMer 
at 1/2, in PBS.
Statistical analyses
One-tailed paired or unpaired t-test was applied on data sets 
with a normal distribution, whereas one-tailed Mann-Whitney 
(unpaired test) or Wilcoxon (matched-paired test) tests were used 
otherwise. P < 0.05 was considered statistically significant. Cor-
relations were evaluated using the Pearson’s test. For biomarker 
measurements, a ROC curve was generated. The AUC value and 
95% CI were calculated to determine the specificity and sensitiv-
ity of TB infection. All statistical analyses were performed using 
GraphPad Prism 6.0 (GraphPad Software Inc., USA).
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